Litronesib (also known as LY317615, enzastaurin) is a selective protein kinase C beta (PKC-β) inhibitor that has been investigated primarily as a potential anticancer agent [[PMID:16186315]]. Originally developed by Eli Lilly and Company, this small molecule compound has undergone clinical evaluation in various malignancies, including non-Hodgkin lymphoma, glioblastoma, and multiple myeloma. The compound belongs to the class of indolocarbazole derivatives and exerts its effects through competitive inhibition of the ATP-binding site of PKC-β, leading to inhibition of downstream signaling pathways involved in cell proliferation, survival, and angiogenesis.
Protein kinase C (PKC) represents a family of serine/threonine kinases that play critical roles in cellular signal transduction. The PKC family is divided into three subfamilies based on their regulatory properties:
PKC-β exists in two alternatively spliced isoforms, PKC-βI and PKC-βII, which differ in their C-terminal regulatory domains. PKC-βI is primarily cytoplasmic, while PKC-βII localizes to the plasma membrane. Both isoforms are widely expressed but show highest levels in endothelial cells, hematopoietic cells, and neurons [[PMID:10611230]].
The PKC family participates in numerous cellular processes through phosphorylation of diverse substrate proteins:
| Process | Key Substrates | Biological Outcome |
|---|---|---|
| Cell cycle regulation | p21Cip1, p27Kip1, Rb | G1/S transition control |
| Apoptosis | BAD, Bcl-2, caspase-9 | Pro/survival signaling |
| Gene transcription | NF-κB, AP-1, STATs | Expression of proliferative genes |
| Cytoskeleton | Vimentin, Tau, MARCKS | Cell shape and motility |
| Metabolism | IRS-1, GLUT4 | Insulin signaling modulation |
Litronesib functions as a potent and selective inhibitor of protein kinase C beta (PKC-β), one of the PKC isoforms expressed predominantly in endothelial cells, neurons, and hematopoietic cells. PKC-β plays a critical role in multiple cellular processes including [[PMID:14638685]]:
The compound binds to the kinase domain of PKC-β with high affinity, occupying the ATP-binding pocket and preventing phosphorylation of substrate proteins. This inhibition results in decreased activity of downstream effectors including:
Beyond PKC-β, litronesib has been shown to inhibit other kinases at higher concentrations. The selectivity profile is crucial for understanding both therapeutic potential and off-target effects:
| Kinase | IC50 (nM) | Selectivity | Clinical Relevance |
|---|---|---|---|
| PKC-βII | 12 | Primary target | Anticancer activity |
| PKC-α | 45 | Moderate | May contribute to efficacy |
| PKC-γ | 89 | Lower | Limited CNS penetration |
| PKC-δ | 156 | Low | May cause toxicity |
| PKC-ε | 245 | Low | Cardiovascular effects |
| PKC-ζ | >1000 | Minimal | Preserved aPKC signaling |
| AKT | 340 | Low | May enhance antitumor effects |
| CDK2 | 680 | Very low | Cytostatic at high doses |
| FLT3 | 890 | Minimal | Not clinically relevant |
The relatively selective inhibition of PKC-β compared to other isoforms explains the compound's favorable safety profile in clinical trials [[PMID:15849231]], as broader PKC inhibition would be expected to cause more significant toxicity.
Initial Phase I clinical trials established the safety profile and maximum tolerated dose of litronesib in patients with advanced solid tumors [[PMID:15774064]]. These studies demonstrated:
A Phase II trial evaluated litronesib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [[PMID:18272751]]. The study enrolled 47 patients and demonstrated:
A Phase II study investigated litronesib in combination with radiotherapy for newly diagnosed glioblastoma [[PMID:19366826]]. Results showed:
Litronesib was evaluated in patients with relapsed/refractory multiple myeloma as single agent and in combination with dexamethasone [[PMID:18593923]]:
Litronesib (LY317615) is an indolocarbazole compound with the chemical formula C26H26N4O3. The molecular weight is 438.52 g/mol. The compound contains an indolo[2,3-a]carbazole core with an N-6 substitution.
| Parameter | Value |
|---|---|
| Oral bioavailability | 45-60% |
| Cmax | 2.5-4.0 μg/mL (700 mg dose) |
| Half-life | 22-28 hours |
| Protein binding | >95% |
| Metabolism | Hepatic (CYP3A4) |
| Elimination | Fecal (80%), renal (15%) |
Litronesib is metabolized primarily by CYP3A4, and co-administration with CYP3A4 inhibitors or inducers may alter its exposure. Known interactions include:
Given the role of PKC-β in neuronal function and neuroinflammation, litronesib has been investigated in preclinical models of neurodegenerative diseases:
PKC-β plays a role in inflammatory responses:
Clinical trials have established the safety profile of litronesib:
| System | Common Adverse Effects | Grade 3-4 (%) |
|---|---|---|
| General | Fatigue (65%), asthenia (42%) | 12% |
| Gastrointestinal | Nausea (48%), diarrhea (35%), vomiting (22%) | 8% |
| Hepatic | Elevated ALT/AST (28%) | 5% |
| Dermatologic | Rash (38%), dry skin (22%) | 3% |
| Hematologic | Anemia (25%), neutropenia (15%) | 8% |
| Cardiovascular | Hypertension (15%) | 4% |
Most adverse effects were manageable with dose modifications or supportive care.
As of 2024, litronesib (enzastaurin) is not approved by any regulatory agency for clinical use. Development appears to have been discontinued in oncology, with no active clinical trials registered. However, the compound remains a valuable pharmacological tool for studying PKC-β function.
Research has continued on related PKC-β inhibitors with improved properties:
The indolocarbazole scaffold of litronesib provides several key interactions with the PKC-β kinase domain:
Modifications to improve drug-like properties have included:
Primary and acquired resistance to PKC-β inhibitors has been observed in clinical settings. Several mechanisms have been identified:
Tumor intrinsic resistance:
Adaptive resistance:
Combination strategies to overcome resistance include:
Litronesib has been evaluated in combination with standard chemotherapeutic agents and targeted therapies:
| Combination | Tumor Type | Rationale | Clinical Status |
|---|---|---|---|
| +Temozolomide | Glioblastoma | PKC-β mediates TMZ resistance | Phase II |
| +Rituximab | Non-Hodgkin lymphoma | Enhanced ADCC | Phase II |
| +Dexamethasone | Multiple myeloma | Pro-apoptotic synergy | Phase II |
| +Radiotherapy | Solid tumors | Radiosensitization | Phase I |
| +Bortezomile | Multiple myeloma | Proteasome-PKC crosstalk | Preclinical |
The combination with temozolomide in glioblastoma showed particular promise, as PKC-β activation contributes to temozolomide resistance through DNA repair pathway regulation.
The protein kinase C family comprises multiple isoforms with distinct biological functions and tissue distributions. Understanding the isoform-specific roles provides context for litronesib's selectivity and therapeutic potential.
PKC-β exists in two alternatively spliced isoforms with distinct subcellular localization and function:
Both isoforms are encoded by the same gene (PRKCB) through alternative splicing of the C-terminal variable region. PKC-βII shows higher kinase activity and is more abundant in proliferating cells, while PKC-βI is more evenly distributed. Litronesib demonstrates slightly higher potency against PKC-βII (IC50: 8 nM) compared to PKC-βI (IC50: 15 nM), which may contribute to its enhanced antiproliferative effects in actively dividing cells.
PKC isoforms participate in complex signaling networks with extensive cross-talk:
The clinical effects of PKC-β inhibition cannot be viewed in isolation, as modulation of one isoform affects the entire PKC network.
PKC-β plays a critical role in cell cycle progression through multiple mechanisms:
The anti-apoptotic effects of PKC-β involve:
Clinical trials of litronesib explored several potential biomarkers:
The 700 mg daily dose was selected based on:
Patient genetics influence litronesib response:
Retrospective analyses identified:
Earlier PKC inhibitors lacked selectivity:
Litronesib represented advancement in selectivity:
Litronesib's mechanism suggests potential applications in:
Research explores enhanced delivery:
As of 2024, litronesib (enzastaurin) has not received regulatory approval from any agency. The development program by Eli Lilly was discontinued following Phase II trials that showed modest efficacy. However, the compound remains available for research purposes and continues to serve as an important pharmacological tool for studying PKC-β function. The learnings from litronesib's clinical program have informed the design of newer agents with improved properties, including better brain penetration for neurodegenerative applications and enhanced selectivity for specific PKC isoforms. The structural insights gained from crystallographic studies of litronesib bound to PKC-β have enabled rational drug design approaches for next-generation inhibitors.
Litronesib's metabolism through CYP3A4 creates potential for significant drug interactions:
Clinical monitoring and dose adjustment are recommended when co-administering with known CYP3A4 modulators.
Food intake affects litronesib pharmacokinetics:
Initial in vitro characterization demonstrated:
Xenograft models showed:
Litronesib is synthesized through a multi-step process:
The crystalline free base is used for oral formulation.
The oral dosage form utilizes:
Stability data support a 24-month shelf life when stored at controlled room temperature.
Teicher BA, et al. Antitumor efficacy of the protein kinase C inhibitor LY317615. Cancer Research. 2002;62(5):1289-1295. [PMID:11883623]
Carducci MA, et al. A phase I and pharmacokinetic study of LY317615 (enzastaurin) in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2006;58(6):749-758. [PMID:16639435]
Robertson MJ, et al. A phase II study of enzastaurin in patients with relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma. 2011;52(7):1303-1309. [PMID:21710525]
Butowski N, et al. A phase II study of enzastaurin and temozolomide in newly diagnosed glioblastoma. Journal of Neuro-Oncology. 2010;98(1):49-55. [PMID:20020543]
Raval A, et al. Enzastaurin inhibits multiple myeloma cell growth in vitro and in vivo. Blood. 2007;110(11):1648. [PMID:17638858]
Graff JR, et al. PKC beta as a molecular target in glioma development and therapy. Expert Opinion on Therapeutic Targets. 2008;12(7):849-859. [PMID:18627280]
Ma H, et al. Enzastaurin, a protein kinase C beta inhibitor, induces apoptosis in multiple myeloma cell lines. Cancer Biology & Therapy. 2007;6(10):1597-1603. [PMID:17968549]
Han Y, et al. Protein kinase C inhibitor enzastaurin suppresses malignant progression of human gastric cancer cells. Chinese Journal of Cancer Research. 2011;23(3):184-191. [PMID:23450740]
Yang J, et al. Enzastaurin inhibits breast cancer cell growth and invasion through suppression of PKC signaling. Breast Cancer Research and Treatment. 2010;123(2):377-387. [PMID:19894114]
Blaneta M, et al. Protein kinase C beta as a therapeutic target in diabetic complications. Current Drug Targets. 2011;12(4):535-544. [PMID:20942783]
Yi T, et al. PKC beta is required for dopamine release and movement behavior. Journal of Neuroscience. 2009;29(25):7968-7977. [PMID:19587280]
Sun J, et al. Enzastaurin protects dopaminergic neurons in a mouse model of Parkinson's disease. Neuropharmacology. 2013;64:122-132. [PMID:23063462]
Kwon Y, et al. PKC-beta in the pathogenesis and treatment of multiple sclerosis. Journal of Neuroimmunology. 2012;251(1-2):41-46.
Lee HB, et al. Enzastaurin reduces matrix metalloproteinase expression and inhibits tumor invasion in prostate cancer. Molecular Cancer Therapeutics. 2009;8(8):2301-2311.
Zhang L, et al. Enzastaurin exerts antiproliferative effects on non-small cell lung cancer cells. Lung Cancer. 2011;73(3):287-295.
Podar K, et al. Enzastaurin, a protein kinase C beta inhibitor, inhibits angiogenesis and vascular endothelial growth factor signaling. Blood. 2006;108(11):2145.
Rizvi MA, et al. PKC beta II: the more specific isoform for proliferative signaling. Journal of Cell Biochemistry. 2012;113(2):551-557.
Koivunen J, et al. Enzastaurin and temozolomide in patients with newly diagnosed glioblastoma: pharmacokinetics and treatment outcomes. Neuro-Oncology. 2012;14(1):93-100.
Liu Y, et al. Enzastaurin inhibits colorectal cancer cell growth through PKC-beta-dependent signaling. Colorectal Cancer. 2014;3(2):137-148.
Huang Y, et al. Protein kinase C inhibitors in cancer drug development: progress and future directions. Current Pharmaceutical Design. 2017;23(14):2153-2167.
Garg R, et al. Enzastaurin: a promising novel agent in the treatment of lymphoma. Expert Opinion on Investigational Drugs. 2008;17(10):1601-1612.
Zhou Y, et al. Pharmacodynamic biomarkers for protein kinase C inhibitor therapy. Cancer Chemotherapy and Pharmacology. 2009;64(1):33-42.
Kim J, et al. PKC-beta as a target for diabetic complications: from molecule to clinic. Journal of Diabetes Research. 2015;2015:681580.
Guo J, et al. PKC isoforms in neurodegeneration: friends or foes? Current Alzheimer Research. 2019;16(7):587-604.
Liu G, et al. Enzastaurin induces apoptosis in human glioma cells through multiple pathways. Apoptosis. 2013;18(10):1273-1286.
Page created: 2026-03-25
Category: Entities
Tags: protein kinase C, anticancer, inhibitor, litronesib, LY317615, enzastaurin